title: Mechanisms of protection by S-allylmercaptocysteine against acetaminophen-induced liver injury in mice.
abstract: S-Allylmercaptocysteine (SAMC), one of the water-soluble organosulfur compounds in ethanol extracts of garlic (Allium sativum L.), has been shown to protect mice against acetaminophen (APAP)-induced liver injury. In this study, we examined the mechanisms underlying this hepatoprotection. SAMC (100 mg/kg, p.o.) given 2 and 24 hr before APAP administration (500 mg/kg, p.o.) suppressed the plasma alanine aminotransferase activity increases 3 to 12 hr after APAP administration significantly. The hepatic reduced glutathione levels of vehicle-pretreated mice decreased 1 to 6 hr after APAP administration, but SAMC pretreatment suppressed the reductions 1 to 6 hr after APAP administration significantly. These inhibitory effects of SAMC were dose-dependent (50-200 mg/kg) 6 hr after APAP administration. As SAMC pretreatment (50-200 mg/kg) suppressed hepatic cytochrome P450 2E1-dependent N-nitrosodimethylamine demethylase activity significantly in a dose-dependent manner, we suggest that one of its protective mechanisms is inhibition of cytochrome P450 2E1 activity. SAMC pretreatment also suppressed the increase in hepatic lipid peroxidation and the decrease in hepatic reduced coenzyme Q9 (CoQ9H2) levels 6 hr after APAP administration. The hepatic CoQ9H2 content of the SAMC pretreatment group was maintained at the normal level. Therefore, we suggest that another hepatoprotective mechanism of SAMC may be attributable to its antioxidant activity.
authors.affiliation: Institute for OTC Research, Wakunaga Pharmaceutical Co., Ltd., Hiroshima, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Sumioka
authors.forename: T
authors.initials: T
authors.lastname: Matsura
authors.forename: S
authors.initials: S
authors.lastname: Kasuga
authors.forename: Y
authors.initials: Y
authors.lastname: Itakura
authors.forename: K
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000082:Acetaminophen / Q000009:adverse effects*; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury; D003067:Coenzymes; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D019392:Cytochrome P-450 CYP2E1 / Q000187:drug effects / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000187:drug effects / Q000378:metabolism; D005978:Glutathione / Q000187:drug effects / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008107:Liver Diseases / Q000517:prevention & control*; D008297:Male; D051379:Mice; D011506:Proteins / Q000187:drug effects / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000378:metabolism; D015238:Sulfotransferases / Q000187:drug effects / Q000378:metabolism; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000187:drug effects / Q000378:metabolism; D014810:Vitamin E / Q000378:metabolism
chemical_list: D003067:Coenzymes; D011506:Proteins; C086300:S-allylmercaptocysteine; D013438:Sulfhydryl Compounds; D014451:Ubiquinone; D014810:Vitamin E; D000082:Acetaminophen; D019392:Cytochrome P-450 CYP2E1; D014453:Glucuronosyltransferase; D000410:Alanine Transaminase; D015238:Sulfotransferases; C024989:coenzyme Q10; D005978:Glutathione; D003545:Cysteine; C030571:ubiquinone 9